Open Access Articles- Top Results for VEGF receptors

VEGF receptors

fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
Symbol FLT1
Alt. symbols FLT
Entrez 2321
HUGO 3763
OMIM 165070
RefSeq NM_002019
UniProt P17948
Other data
EC number
Locus Chr. 13 q12
kinase insert domain receptor (a type III receptor tyrosine kinase)
Symbol KDR
Alt. symbols FLK1, VEGFR, VEGFR2, CD309
Entrez 3791
HUGO 6307
OMIM 191306
RefSeq NM_002253
UniProt P35968
Other data
EC number
Locus Chr. 4 q11-q12
fms-related tyrosine kinase 4
Symbol FLT4
Alt. symbols VEGFR3, PCL
Entrez 2324
HUGO 3767
OMIM 136352
RefSeq NM_002020
UniProt P35916
Other data
EC number
Locus Chr. 5 q34-q35

VEGF receptors are receptors for vascular endothelial growth factor (VEGF).[1][2] There are three main subtypes of VEGFR, numbered 1, 2 and 3. Also, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR), depending on alternative splicing.[3]


Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the formation of the circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). As its name implies, VEGF activity is restricted mainly to cells of the vascular endothelium, although it does have effects on a limited number of other cell types (e.g. stimulation monocyte/macrophage migration). In vitro, VEGF has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF also enhances microvascular permeability and is sometimes referred to as vascular permeability factor.

Receptor biology

File:VEGF receptors.png
Ligands for different VEGF receptors.[4][5]

All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors (the VEGFRs) on the cell surface, causing them to dimerize and become activated through transphosphorylation. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain.

VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.[1] The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 is to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In fact, an alternatively spliced form of VEGFR-1 (sFlt1) is not a membrane bound protein but is secreted and functions primarily as a decoy.[6] A third receptor has been discovered (VEGFR-3), however, VEGF-A is not a ligand for this receptor. VEGFR-3 mediates lymphangiogenesis in response to VEGF-C and VEGF-D.

VEGFR antagonists

Some VEGFR antagonists (inhibitors) (for example lenvatinib, motesanib) are under investigation for treating various cancers. Pazopanib was approved for renal cell carcinoma in 2009. Regorafenib was approved for colorectal cancer in Sept 2012.


  1. ^ a b Holmes K, Roberts OL, Thomas AM, Cross MJ. (Oct 2007). "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.". Cell Signal. 19 (10): 2003–2012. PMID 17658244. doi:10.1016/j.cellsig.2007.05.013. 
  2. ^ Stuttfeld E, Ballmer-Hofer K (September 2009). "Structure and function of VEGF receptors". IUBMB Life 61 (9): 915–22. PMID 19658168. doi:10.1002/iub.234. 
  3. ^ Fujita, N.; Imai, J.; Suzuki, T.; Yamada, M.; Ninomiya, K.; Miyamoto, K.; Iwasaki, R.; Morioka, H.; Matsumoto, M.; Chiba, K.; Watanabe, S.; Suda, T.; Toyama, Y.; Miyamoto, T. (2008). "Vascular endothelial growth factor-A is a survival factor for nucleus pulposus cells in the intervertebral disc". Biochemical and Biophysical Research Communications 372 (2): 367–372. PMID 18492486. doi:10.1016/j.bbrc.2008.05.044.  edit
  4. ^
  5. ^ Interactions of VEGF ligands and VEGF receptors, retrieved on November 13, 2009
  6. ^ Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres-Vázquez J. (August 2011). "Semaphorin-PlexinD1 Signaling Limits Angiogenic Potential via the VEGF Decoy Receptor sFlt1". Dev Cell. 21 (2): 301–314. PMC 3156278. PMID 21802375. doi:10.1016/j.devcel.2011.06.033. 

External links